

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application.

**Listing of Claims:**

Claims 1-4 (Canceled)

Claim 5 (Original): A method for determining the sensitivity of a proliferative disease in a subject to treatment with an mTOR inhibitor, comprising determining the level of expression and/or phosphorylation state of S6 in a sample derived from the subject.

Claim 6 (Previously presented): A method according to claim 5, wherein the proliferative disease comprises a cancer.

Claim 7 (Previously presented): A method according to claim 5, wherein the mTOR inhibitor comprises rapamycin or a rapamycin derivative.

Claim 8 (Previously presented): A method according to claim 7, wherein the rapamycin derivative comprises 40-O-(2-hydroxyethyl) rapamycin.

Claim 9 (Previously presented): A method according to claim 5, comprising determining the level of expression of phosphorylated S6 protein.

Claim 10 (Previously presented): A method according to claim 5, wherein the sample is derived from a tumor in the subject.

Claims 11-13 (Canceled)